Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from GSK

FDA Approves ViiV Healthcare's Cabenuva For Virologically Suppressed Adolescents With HIV

The FDA has approved ViiV Healthcare's Cabenuva (cabotegravir, rilpivirine) for HIV-1 in virologically suppressed adolescents. The approval covers patients aged 12 years or older and weighing at least 35kg on a stable antiretroviral regimen, with no history of treatment failure and no known or suspected resistance to either cabotegravir or rilpivirine. The regimen…

Benzinga · Mar 29, 2022

FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant

The FDA said that the currently authorized 500mg dose of GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) COVID-19 antibody therapy is unlikely to be effective against the omicron BA.2 variant. The agency updated its website to exclude sotrovimab use in geographic regions where the infection is likely caused by the omicron BA.2 variant. GSK…

Benzinga · Mar 28, 2022

KTR showcases Telangana to pharma majors

Meets top leadership of Pfizer, Johnson & Johnson and GSK as part of his official tour to the US

The Hindu · Mar 26, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

LifeMine Therapeutics, GSK Ink $70M Drug Discovery, Development Pact

LifeMine Therapeutics Inc, a drug discovery startup that uses genetically-encoded small molecules, has partnered with GlaxoSmithKline plc (NYSE:GSK) to discover and develop drugs from fungal genomes. GSK will bring three targets for LifeMine to run through its proprietary drug discovery platform, which scans for fungi that could be a match to create a…

Benzinga · Mar 23, 2022

Workers at GSK to vote on possible strike action over pay offer

Around 150 workers at the company's plant in Barnard Castle have rejected a 4% pay offer

Birmingham Post · Mar 21, 2022

GlaxoSmithKline says it will not start any new clinical trials in Russia

Pharma firm joins AstraZeneca and Pfizer in saying it will not enrol new patients into studies

The Guardian - UK · Mar 17, 2022

GSK halts new clinical trials in Russia but continues supply of medicines

The company is the latest drug-maker to take such steps, although the healthcare sector has not pulled out of the region entirely.

The Independent UK · Mar 17, 2022

Read news from The Economist, FT, and more,
with one subscription

Europe Kickstarts Reviewing AstraZeneca Application For Its COVID Antibody

European Medicines Agency has started reviewing AstraZeneca Plc's (NASDAQ:AZN) application for antibody-based COVID-19 therapy but gave no timeline for a conclusion. Infections from COVID-19 are still rising in parts of the world, including Europe. On Tuesday, China posted a steep jump in daily COVID-19 infections, with new cases more than doubling from a…

Benzinga · Mar 16, 2022

GSK/Vir Biotech's COVID-19 Antibody Associated With Resistance Mutations, New Research Shows

According to new research in Australia, some people have developed sotrovimab-resistant mutations following infusions with the GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc (NASDAQ:VIR) monoclonal antibody with COVID-19 infection. Data shows that the mutations have been associated with a reduction by a factor of 100 to 297 in neutralization by sotrovimab. "These data show the persistence…

Benzinga · Mar 11, 2022

BP and Shell lead rush to exit Russia. There can be no going back

Oil is always a political business, and there’s no point pretending otherwise

The Guardian - UK · Feb 28, 2022

GSK boss upbeat over spin-off of consumer healthcare unit

Expected to be the biggest London listing in a decade, the Haleon demerger is scheduled for July

The Guardian - UK · Feb 28, 2022

GSK Stops Additional Three Respiratory Virus Vaccine Trials In Pregnant Women

GlaxoSmithKline Plc (NYSE: GSK) has halte

Benzinga · Feb 28, 2022

GSK Halts 3 Trials of Respiratory Virus Vaccine in Pregnant Women

Britain's GSK said on Monday it had halted enrollment and vaccination in three trials of its experimental vaccine against the respiratory syncytial virus (RSV) in pregnant women, the latest setback in developing a vaccine for the microbe. GSK said on Feb.

Asharq Al-Awsat · Feb 28, 2022

Russian central bank hikes rates and closes stock market as rouble crashes; oil and gas soar – as it happened

Commodities including wheat and aluminium surge and European stocks slide as markets respond to wider sanctions on Russia

The Guardian - UK · Feb 28, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Feb 25, 2022

Does CBD Have To Be Water Soluble? One Group Of Scientists Say Yes For Better Absorption

Several former scientists and staff from companies like Johnson & Johnson (NYSE: JNJ), GlaxoSmithKline (NYSE: GSK) and Schiff Nutrition are bringing a new delivery platform to market that boosts the bioavailability of&

Benzinga · Feb 25, 2022

AstraZeneca, GSK's COVID-19 Therapies Lose Efficacy Against Omicron's Subvariants

The FDA authorized an increased dose in the case of AstraZeneca Plc's (NASDAQ:

Benzinga · Feb 25, 2022

Canada Approves First Plant-Based COVID-19 Vaccine

As Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc's (NYSE: GSK) COVID-19 vaccine finally heads to regulators, another shot using GSK's pandemic adjuvant has

StockNews.com · Feb 24, 2022

5 Defensive Stocks to Own for Consistent Dividends and Stable Earnings

Concerns over the Russia-Ukraine war and high inflation have significantly affected the global equity markets lately. As the stock market is expected to remain highly volatile in the coming weeks, it could be wise to bet on defensive stocks Walmart (WMT), Novartis (NVS), Merck & Co. (MRK), GlaxoSmithKline (GSK), and…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Feb 23, 2022

Sanofi-GSK Prepare Regulatory Filings For COVID-19 Vaccine After Booster Data

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) are

The Guardian - UK · Feb 23, 2022

Sanofi and GSK seek approval for Covid-19 vaccine

The drugmakers hope to catch up with rivals after reporting positive results from late-stage clinical trials

The Guardian - UK · Feb 22, 2022

GSK unveils its new consumer brands spin-off name: Haleon

Products such as Voltaren, Sensodyne and Panadol to regroup under new stock market listing in summer

Evening Standard · Feb 22, 2022

Hello, Haleon: GlaxoSmithKline reveals name of £60bn consumer health spin-out

THE new consumer healthcare company to be spun out from GlaxoSmithKline will be named Haleon, it was announced today.

Benzinga · Feb 18, 2022

GSK Halts Late-Stage RSV Vaccine Trial In Pregnant Women

GlaxoSmithKline plc (NYSE: GSK) has paused a late

Benzinga · Feb 18, 2022

The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga · Feb 10, 2022

Preprint Suggests, Vir-GSK's COVID-19 Antibody Can Evade Omicron Sub-Variant

In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc (NYSE

1 … 15 16 17 18

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

European Central Bank

307 stories

MRK

234 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.